November 1, 2010
Glytec Insulin Dosing Software Now Compatible with BlackBerry, Android, and iPhone
The G+ Enterprise Edition software is now compatible with select Android, BlackBerry, and iPhone devices, including the new iPhone 4 and iPad.
Glytec, LLC, a leader in glycemic management solutions, announced today that it has released a new enhancement to its inpatient blood glucose management software. The G+ Enterprise Edition software is now compatible with select Android, BlackBerry, and iPhone devices, including the new iPhone 4 and iPad.
The G+ Enterprise Edition software provides both intravenous and subcutaneous dosing recommendations of insulin and glucose and can be accessed from any computer within a hospital’s network. Users with mobile devices can now access real-time patient information, allowing for better monitoring of insulin dosing and blood glucose levels.
“Providing clinicians rapid access to a patient’s glycemic profile, especially during a period of critical illness, will help to improve overall quality of care,” said Dr. Robert Fischell, CEO of Glytec.
About Glytec, LLC
Glytec, LLC, is a privately held company based in Greenville, South Carolina. The company’s first generation glycemic management system, Glucommander Plus, received FDA 510(k) clearance in May 2006. In July 2010, the company announced it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next generation G+ System Enterprise Edition, insulin management software system. The system incorporates new innovative features including algorithm enhancements, additional predictive warnings and alerts, a fully-integrated and real-time reporting engine, and precision bolus dosing of meal-time insulin. For more information about Glytec, please visit www.glytecsystems.com.
The published Indications for Use of the G+™ System as a prescriptive device are described on the FDA’s website under Reference K101344.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
